Ataluren Phase 2 Data In Nonsense Mutation Cystic Fibrosis Published In The European Respiratory Journal
Originally posted in Cystic Fibrosis News From Medical News Today
PTC Therapeutics, Inc. (PTC) announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal…
No Comments »
RSS feed for comments on this post. TrackBack URL
by Raelene
